Is NCT07277413 recruiting in East Brunswick, NJ?

Yes, NCT07277413 is currently recruiting participants at its East Brunswick, NJ location. This nsclc adenocarcinoma clinical trial is actively enrolling qualified participants.

How do I join the nsclc adenocarcinoma clinical trial in East Brunswick?

To join this clinical trial in East Brunswick, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this East Brunswick clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

NSCLC Adenocarcinoma Clinical Trial in East Brunswick, NJ

About This NSCLC Adenocarcinoma Study in East Brunswick

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Sponsor: IDEAYA Biosciences

Who Can Participate

Inclusion Criteria

Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.

Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma \[pleural or peritoneal\], gastroesophageal cancers \[squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers\], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC \[adenocarcinoma, squamous cell carcinoma, and adeno-squamous\] or UC \[including mixed urothelial-squamous histology\]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).

Are willing and able to provide blood/tumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.

Must be willing and able to provide the blood/serum/plasma samples

Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)

Have at least 1 measurable lesion according to RECIST version 1.1

Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1

Have life expectancy \> 3 months

Have adequate bone marrow and organ function

Able to swallow and retain orally administered study drug/IMP.

Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures

Male and female: willing to use contraception

Exclusion Criteria

Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids

Have a known primary central nervous system (CNS) malignancy

Have had other malignancies within 2 years prior to the first dose, with some exceptions

Impaired cardiac function or clinically significant cardiac diseases

Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter

Have a history of severe infections within 4 weeks prior to the start of study treatment

Hypertension (e.g., \> 150/100 mmHg) that cannot be controlled by medications despite optimal medical therapy

Other acute or chronic medical or psychiatric condition

Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening

Known or suspected viral hepatitis with a positive test at screening

Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1

Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks

Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP

Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein

Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4/5, Strong inhibitors of P-gp and/or BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP

Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study

Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892

Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and/or Protein arginine N-methyltransferase (PRMT) inhibitor

Major surgery within 4 weeks before study entry

Prior irradiation to \> 25% of the bone marrow

Known or suspected hypersensitivity to IDE892 Disease-Specific Eligibility Criteria Eligibility Criteria for Participants with NSCLC (All Parts)

Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1/PD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting

Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.

If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy. Eligibility Criteria for Participants with Urothelial Cancer (Bladder and Upper Urinary Tract), Mesothelioma (Pleural or Peritoneal), Pancreatic Adenocarcinoma or Biliary Tract Carcinomas (Intrahepatic and Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer) (Parts 1 and 3)

Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors

Must have progressed following at least 1 prior line of therapy

Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in East Brunswick?

Yes, this clinical trial (NCT07277413) has an active research site in East Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

NSCLC Adenocarcinoma Treatment Options in East Brunswick, NJ

If you're searching for nsclc adenocarcinoma treatment options in East Brunswick, NJ, this clinical trial (NCT07277413) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our East Brunswick research site is actively enrolling participants for this clinical trial. You'll receive care from experienced nsclc adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all nsclc adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

NSCLC Adenocarcinoma Clinical Trial in East Brunswick, NJ

Expert Care in East Brunswick

IRB Approved

No-Cost Care

Apply for This East Brunswick Location

Why Participate?

Simple Process